| [1] |
Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia[J]. Blood, 1997, 90(2):479-488.
|
| [2] |
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon, France:IARC, 2008.
|
| [3] |
Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia[J]. Br J Hematol, 2011, 152(6):677-687.
|
| [4] |
Passmore SJ, Chessells JM, Kempski H. et al. Pediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK:A population-based study of incidence and survival[J]. Br J Haematol, 2003, 121(5):758-767.
|
| [5] |
Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: A retrospective analysis of 110 cases[J]. Blood, 1997, 89(10):3534-3543.
|
| [6] |
Liu XL, Wan Z, Wu JR, et al. The clinical diagnosis of JMML[J/CD]. Chin J Obstet Gynecol Pediatr:Electron Ed, 2012, 8(3):332-334.
|
| [7] |
Yoshimi A, Kojima S, Hirano N. Juvenile myelomonocytic leukemia epidemiology, etiopathogenesis, diagnosis, and management considerations[J]. Pediatr Drugs, 2010, 12 (1):11-21.
|
| [8] |
Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: A retrospective study of 189 patients in Japan[J]. Leukemia, 2001, 15(11):1713-1720.
|
| [9] |
Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: Weaving a tumorigenic web[J]. Nat Rev Cancer, 2011, 11(11):761-774.
|
| [10] |
Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia[J]. Nat Genet, 2003, 34 (2):148-150.
|
| [11] |
Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase[J]. Blood, 2007, 109 (3):862-867.
|
| [12] |
Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2[J]. Cell, 1998, 92 (4):441-450.
|
| [13] |
Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1[J]. Blood, 1998, 92 (1):267-272.
|
| [14] |
Muramatsu H, Makishima H, Jankowska AM, et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia[J]. Blood, 2010, 115(10):1969-1975.
|
| [15] |
Pasmant E, Ballerini P, Lapillonne H, et al. SPRED1 disorder and predisposition to leukemia in children[J]. Blood, 2009, 114(5):1131.
|
| [16] |
Aucagne R, Droin N, Paggetti J, et al. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia[J]. J Clin Invest, 2011, 121(6):2361-2370.
|
| [17] |
Zenker M. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors[J]. Curr Opin Pediatr, 2010, 23(4):443-451.
|
| [18] |
Tidyman WE, Rauen KA. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation[J]. Curr Opin Genet Dev, 2009, 19(3):230-236.
|
| [19] |
Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia[J]. Leukemia, 2008, 22(7):1335-1342.
|
| [20] |
Chan RJ, Cooper T, Kratz CP, et al. Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium[J]. Leuk Res, 2009, 33(3):355-362.
|
| [21] |
Steelman LS, Franklin RA, Abrams SL, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy[J]. Leukemia, 2011, 25(7):1080-1094.
|